LACTOLOGY FOUNDATION

Poldine (ATC A03AB11) is a synthetic quaternary ammonium antimuscarinic used as an antispasmodic for functional gastrointestinal disorders; during lactation it should generally be avoided for repeated or long‑term use, with only occasional short courses considered and accompanied by careful monitoring of the breastfed infant for anticholinergic adverse effects.medpedia.framar+5

Pharmacological class and indications

ATC group A03AB comprises synthetic anticholinergics that are quaternary ammonium compounds used mainly for functional gastrointestinal disorders such as irritable bowel–type symptoms, peptic‑ulcer–related hyperacidity and painful smooth‑muscle spasms of the stomach and intestine. Within this group, A03AB11 identifies poldine (also known as poldine methylsulfate), a peripherally acting antimuscarinic agent classed as an antispasmodic for smooth muscle of the gastrointestinal tract.drugbank+4

Poldine is typically used to reduce abdominal pain, cramping, bloating and motility disturbances in functional bowel disorders and related conditions, usually as adjunctive symptomatic therapy rather than disease‑modifying treatment. Like other quaternary ammonium anticholinergics, it is formulated for oral use and is generally supplied as a prescription‑only medicinal product.atcddd.fhi+3

Mechanism of action and pharmacodynamics

Poldine acts as a competitive antagonist at muscarinic acetylcholine receptors (primarily M1 and M3 subtypes) on gastrointestinal smooth muscle and secretory cells. By blocking parasympathetic cholinergic input, it reduces smooth‑muscle tone and motility and diminishes gastrointestinal secretions, producing an antispasmodic, anticholinergic effect similar in principle to other GI antimuscarinics.clevelandclinic+2

Because poldine is a quaternary ammonium compound, it has low lipid solubility and limited ability to cross the blood–brain barrier, so central nervous system effects are expected to be less pronounced than with tertiary amine anticholinergics such as atropine. Nevertheless, high doses or susceptible patients may still experience central anticholinergic manifestations, especially if other anticholinergic drugs are co‑administered.goodrx+2

Pharmacokinetics and systemic exposure

Quaternary ammonium anticholinergics given orally are incompletely absorbed from the gastrointestinal tract, leading to relatively low systemic bioavailability and a large proportion of the dose remaining within the gut lumen. The absorbed fraction distributes mainly in the extracellular fluid compartment, with limited penetration into the central nervous system because of the charged quaternary nitrogen and low lipid solubility.drugbank+1

Elimination of this class generally occurs via a combination of hepatic metabolism and renal excretion of parent compound and metabolites, with elimination half‑lives varying between individual agents but often sufficient to support two to three daily doses. In renal impairment, systemic accumulation of polar quaternary ammonium anticholinergics can occur, potentially increasing toxicity and necessitating dose adjustment or avoidance.rch+2

Maternal adverse effects and toxicity

Like other anticholinergic drugs, poldine can cause a characteristic spectrum of dose‑related adverse effects: dry mouth, decreased sweating, constipation, blurred vision, tachycardia and urinary retention. In older adults or patients with pre‑existing cognitive impairment, anticholinergic drugs are associated with confusion, delirium and increased risk of falls, particularly with polypharmacy and prolonged use.clevelandclinic+1

Acute anticholinergic toxicity (“anticholinergic syndrome”) presents with tachycardia, hyperthermia, mydriasis, dry flushed skin, urinary retention, ileus, agitation, hallucinations and, in severe cases, seizures and coma, and is managed supportively with airway protection, fluids, benzodiazepines and, in selected cases, physostigmine. Chronic high anticholinergic burden is linked to increased risk of cognitive decline and cardiovascular events in observational data, so cumulative exposure from multiple agents (e.g. GI antispasmodics, antihistamines, antidepressants) should be minimized, especially in vulnerable populations.goodrx+2

Contraindications and high‑risk groups

Poldine, like other GI antimuscarinics, is contraindicated or should be avoided in patients with conditions where reduced cholinergic tone may worsen disease, including narrow‑angle glaucoma, urinary retention, severe prostatic hypertrophy, paralytic ileus, and certain obstructive gastrointestinal or urogenital disorders. It should also be used cautiously in cardiovascular disease (e.g. tachyarrhythmias), autonomic neuropathy and in elderly patients, where anticholinergic adverse effects and cognitive toxicity are more likely.clevelandclinic+1

From a toxicological standpoint, overdose or combinations with other anticholinergics markedly raise the risk of full‑blown anticholinergic syndrome, requiring prompt recognition and poison‑centre guided management. Patients should be warned against self‑escalation of dose or combining over‑the‑counter anticholinergic products (such as some antihistamines or motion‑sickness remedies) with prescription GI antispasmodics.rch+2

Pregnancy safety considerations

Quaternary anticholinergics like poldine have low oral bioavailability and limited systemic distribution compared with tertiary amines, suggesting a reduced potential for significant fetal exposure, but robust human pregnancy data specific to poldine are sparse. Experience with related anticholinergics in pregnancy has not shown a consistent pattern of major teratogenicity, yet anticholinergics are generally not first‑line in pregnancy and are reserved for clear indications at the lowest effective dose and shortest duration.medsafe+3

When antispasmodic therapy is required in pregnant women, clinicians typically prioritize nonpharmacologic measures and safer, better‑studied drugs, introducing anticholinergics only after individualized risk–benefit evaluation. Potential maternal adverse effects such as tachycardia, constipation and urinary retention may also complicate pregnancy and therefore warrant conservative dosing and close monitoring if poldine is used.medsafe+2

Lactation: pharmacokinetic considerations

Specific data on poldine concentrations in human breast milk and infant serum are lacking, so risk assessment must extrapolate from class properties of quaternary anticholinergics and general principles of drug transfer into milk. Quaternary ammonium compounds are highly polar, have low oral bioavailability and limited penetration into lipid‑rich compartments; these features tend to reduce passage into breast milk and oral absorption by the infant, suggesting low absolute infant exposure when maternal doses are modest.drugbank+2

However, drugs with pharmacologically potent effects at low receptor occupancy can cause clinically significant effects even at very low infant plasma concentrations, and there is no direct evidence to confirm that poldine’s transfer is negligible under all conditions. Moreover, preterm infants or neonates with immature renal function or comorbid disease may clear quaternary anticholinergics more slowly, raising the theoretical risk of accumulation and toxicity.goodrx+3

Potential effects on the breastfed infant

The main theoretical risks for the breastfed infant exposed to poldine via breast milk are manifestations of systemic anticholinergic effects: reduced gastrointestinal motility, constipation, decreased gastric secretions, urinary retention, tachycardia, dry mucous membranes and, rarely, central nervous system symptoms such as irritability, poor feeding, or sedation. These risks are expected to be highest in very young, preterm, low‑birth‑weight or medically complex infants, in whom even small pharmacologic perturbations can have disproportionate clinical impact.rch+3

Because anticholinergics can impair sweating and thermoregulation, a breastfed infant with significant exposure could theoretically be more vulnerable to overheating, especially in hot environments or during illness, though this remains speculative in the absence of case reports specific to poldine. In practice, any infant whose mother is taking a GI anticholinergic should be observed for changes in feeding pattern, stooling, urine output, alertness and weight gain, with prompt medical review if concerning signs emerge.medsafe+2

Maternal lactation and milk production

Anticholinergic agents have the potential to interfere with lactation indirectly by reducing parasympathetic innervation of the breast, potentially affecting milk ejection reflex and breast blood flow, although clinically significant effects on milk production are not well documented for GI antispasmodics. More commonly, maternal anticholinergic adverse effects such as dry mouth, constipation, tachycardia or dizziness may impair overall maternal well‑being and thereby reduce breastfeeding frequency or duration if not adequately managed.clevelandclinic+2

General lactation pharmacology guidance recommends that, when medications with limited lactation data are needed, clinicians should use the lowest effective dose for the shortest possible duration, choose agents with pharmacokinetic profiles that minimize infant exposure, and time doses after feeds where feasible. For poldine, intermittent or short‑course use rather than chronic therapy is more consistent with these principles, especially when treating self‑limited functional gastrointestinal symptoms.drugbank+1

Comparative lactation risk within A03AB

Within ATC A03AB, lactation risk varies according to systemic exposure and clinical need: minimally absorbed local agents such as otilonium bromide are often regarded as relatively compatible with breastfeeding, whereas more systemically active anticholinergics or long‑acting quaternary compounds warrant more caution. Poldine likely occupies an intermediate risk position: not absolutely contraindicated but also not among the preferred first‑line options in breastfeeding women when safer alternatives or nonpharmacologic measures are available.prospectemedicamente+4

For lactating patients requiring antispasmodic therapy, selection should therefore be individualized, taking into account the severity of the mother’s symptoms, the expected duration of treatment, the age and health of the infant, and the availability of alternative therapies with better characterized lactation safety profiles.medsafe+1

Practical breastfeeding recommendations

In a toxico‑lactological framework, routine and prolonged use of poldine during breastfeeding is generally discouraged, particularly in mothers of premature, low‑birth‑weight or medically fragile infants. Short‑term or occasional use may be considered when the expected maternal benefit clearly outweighs potential risks, ideally at the lowest effective dose, with careful observation of the breastfed child for anticholinergic adverse effects.goodrx+3

When clinically feasible, nonpharmacologic strategies (dietary modification, reassurance, management of functional bowel disorders) and alternative drugs with minimal systemic absorption and better documented breastfeeding safety should be tried before initiating poldine. If poldine is used, healthcare professionals should document the indication, treatment duration and counseling provided to the mother, including specific signs and symptoms in the infant that would mandate prompt medical review.rch+2

Duration–risk considerations

Lactation risk with poldine is closely related to treatment duration and cumulative dose: brief courses of a few days for acute functional gastrointestinal episodes are associated with lower theoretical infant exposure than chronic maintenance therapy over weeks or months. Because quaternary anticholinergics are incompletely absorbed and generally have limited bioavailability, intermittent dosing reduces the likelihood of sustained maternal and infant plasma levels, further lowering risk when therapy is short.drugbank+2

By contrast, prolonged daily use increases cumulative maternal anticholinergic burden and raises the probability of both maternal and infant adverse effects, especially in the presence of comorbidities or concomitant anticholinergic medications; in such scenarios, clinicians should re‑evaluate the indication, consider deprescribing, and prioritize safer alternatives.clevelandclinic+2

Summary for healthcare professionals

Poldine (ATC A03AB11) is an antimuscarinic GI antispasmodic that can provide symptomatic relief in functional gastrointestinal disorders but carries the typical anticholinergic adverse effect profile and potential for acute and chronic toxicity. During breastfeeding, its quaternary structure and low bioavailability suggest limited transfer into breast milk, yet the absence of direct lactation data and the sensitivity of neonates to anticholinergic drugs justify a cautious, duration‑limited approach with preference for better‑studied alternatives whenever possible.atcddd.fhi+4

Healthcare professionals should integrate anticholinergic burden, maternal comorbidities, infant characteristics and available alternatives into individualized risk–benefit assessments, documenting their rationale and ensuring clear counseling of breastfeeding women. Such an approach aligns with broader lactation medicine guidance favoring lowest effective doses, shortest treatment durations and careful infant monitoring when medicines with limited lactation data are used.goodrx+2